Abstract
In July, FDA approved two drugs for hepatitis C, daclatasvir (Daklinza—Bristol-Myers Squibb) and a fixed-dose combination of ombitasvir, paritaprevir, and ritonavir (Technivie—AbbVie). Daclatasvir is indicated for the treatment of hepatitis C virus (HCV) genotype 3 chronic infection in combination with sofosbuvir (Sovaldi—Gilead), whereas the combination tablet is indicated to be used in combination with ribavirin for patients with HCV genotype 4 chronic infection without cirrhosis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
